Quinoline and quinazoline compounds useful in therapy

Abstract

Compounds of formula I, wherein R 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms; R 2 represents an aryl group or a heteroaryl group, optionally substituted by C 1-4 alkyl or SO 2 NH 2 ; R 3 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring system as, a whole being optionally substituted; X represents CH or N; and L is absent, or represents a cyclic group of formula Ia, or represents a chain of formula Ib, and pharmaceutically acceptable salts thereof, are useful in the treatment of a variety of disorders including benign prostatic hyperplasia.

1 . A compound of formula I,  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  represents C 1-4  alkoxy optionally substituted by one or more fluorine atoms;  
 R 2  represents an aryl group or a heteroaryl group, optionally substituted by C 1-4  alkyl or SO 2 NH 2 ;  
 R 3  represents a 4-, 5-, 6-, or 7-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring system as a whole being optionally substituted by one or more groups independently selected from OH, C 1-4  alkyl, C 1-4  alkoxy, halogen and NHSO 2 (C 1-4  alkyl), and when S is a member of the ring system, it may be substituted by one or two oxygen atoms;  
 X represents CH or N; and  
 L is absent, 
 or represents a cyclic group of formula Ia,  
                     
 in which A is attached to R 3 ;  
 
 A represents CO or SO 2 ;  
 Z represents CH or N;  
 m represents 1 or 2, and in addition, when Z represents CH, it may represent 0; and  
 n represents 1, 2 or 3, provided that the sum of m and n is 2, 3, 4 or 5; 
 or represents a chain of formula Ib,  
                     
 in which A is attached to R 3 ;  
 
 A and Z are as defined above;  
 R 4  and R 5  independently represent H or C 1-4  alkyl; and  
 p represents 1, 2 or 3, and in addition, when Z represents CH, it may represent 0;  
 or a pharmaceutically acceptable salt thereof.  
 
     
     
         2 . A compound as claimed in  claim 1 , wherein R 1  represents methoxy.  
     
     
         3 . A compound as claimed in  claim 1 , wherein R 2  represents phenyl or 2-pyridinyl.  
     
     
         4 . A compound as claimed in  claim 1 . wherein R 3  represents morpholinyl, car a piperidine ring which is fused to a benzene or pyridine ring.  
     
     
         5 . A compound as claimed in  claim 1 , wherein L is absent or represents  
       
         
           
           
               
               
           
         
       
     
     
         6 . A compound as claimed in  claim 1 , wherein L is absent and R 3  represents a piperidine ring fused to a benzene ring which is substituted by NHSO 2 (C 1-4  alkyl).  
     
     
         7 . A pharmaceutical formulation comprising a compound of formula I, as defined in  claim 1 , or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.  
     
     
         8 . A method of treating benign prostatic hyperplasia, which method comprises administering an effective amount of a compound of formula I, as defined in  claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.